CTLT: Catalent, Inc. Stock

by  •  • Comments Off on CTLT: Catalent, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10,139.99
Enterprise Value ($M) 14,481.99
Book Value ($M) 3,689.00
Book Value / Share 20.38
Price / Book 2.75
NCAV ($M) -3,729.00
NCAV / Share -20.61
Price / NCAV -2.72

Profitability (mra)
Return on Invested Capital (ROIC) -0.15
Return on Assets (ROA) -0.12
Return on Equity (ROE) -0.28

Liquidity (mrq)
Quick Ratio 1.73
Current Ratio 2.47

Balance Sheet (mrq) ($M)
Current Assets 2,578.00
Assets 9,996.00
Liabilities 6,307.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A T. Rowe Price Investment Management, Inc. 6.20 -32.39
02-14 13G Nomura Holdings Inc 6.40
02-13 13G/A Vanguard Group Inc 11.17 3.05
02-13 13G/A Janus Henderson Group Plc 7.30 61.26
02-12 13G/A Veritas Asset Management LLP 3.58 -42.09
02-09 13G/A Capital World Investors 10.60 6.01
01-25 13G/A BlackRock Inc. 9.00 17.31

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202
2023-12-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTIO
2023-12-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20
2023-06-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o
2023-06-12 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ¨ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 71,816 1,615,531 4.45
2024-04-23 62,768 1,349,845 4.65
2024-04-22 109,969 1,633,218 6.73
2024-04-19 103,184 1,588,161 6.50

(click for more detail)

Similar Companies
BHC – Bausch Health Companies Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company EBS – Emergent BioSolutions Inc.
ELAN – Elanco Animal Health Incorporated


Financial data and stock pages provided by
Fintel.io